Breakthrough Therapy Under Investigation for Incurable Cancer

Cytometric Therapeutics believes it has discovered a new therapy that has the potential to become a highly effective way to kill cancer with little toxicity.

This treatment, which is experimental at this time, is being investigated and developed for clinical testing to establish safety and efficacy.

NEWS

Cytometric Therapeutics Raises $40 Million to Advance Clinical Development

Cytometric Therapeutics has secured $40 million in Series A funding. Led by Madison Dearborn Partners founder James N. Perry, this investment wil accelerate its first clinical trial and expand laboratory operations in Huntington Beach, CA. The investment strengthens the company’s mission to develop effective, combination cancer therapies discovered in its Huntington Beach, California laboratory.

Read The Full Announcement >

History

Doctors Larry Weisenthal and William Grace have collaborated for 36 years on testing anti-cancer drugs in the tissue cultures of actual cancer patients.

Discovery

In pursuit of effective therapies, they discovered a new therapy with the goal of treatment to increase dramatically the effectiveness of standard chemotherapeutic agents.

Development

The therapy has been tested on over a dozen types of cancer, and Cytometric Therapeutics is preparing for clinical trials this year.

SynRx™ Functional Precision Oncology

Transforming how cancer therapy is chosen

SynRx™ is a proprietary platform that tests how a patient’s living tumor cells respond to a wide range of cancer drugs and combinations—before treatment begins. By observing real cellular reactions rather than relying on genetic prediction alone, SynRx™ reveals which therapies show the strongest activity for each patient, helping physicians design treatment plans that are both targeted and evidence-based.

Direct Functional Evidence

Combination Insight

Clear Response Mapping

Adaptive Over Time

HOW SynRx™ WORKS